Reuters logo
in 7 months
BRIEF-Ocera Therapeutics reports successful phase 1 clinical study of orally-administered ocr-002 in patients with cirrhosis
January 5, 2017 / 2:14 PM / in 7 months

BRIEF-Ocera Therapeutics reports successful phase 1 clinical study of orally-administered ocr-002 in patients with cirrhosis

1 Min Read

Jan 5 (Reuters) - Ocera Therapeutics Inc :

* Ocera Therapeutics Inc - announces successful phase 1 clinical study of orally-administered ocr-002 in patients with cirrhosis

* Ocera Therapeutics Inc - company plans to initiate phase 2a in h1 2017 with new optimized tablet formulation

* Ocera Therapeutics Inc- ocr-002 was observed to be safe and well-tolerated across all treatment arms in study

* Ocera Therapeutics Inc - ocr-002 demonstrated absolute oral bioavailability of greater than 95 pct in fasted state Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below